Drug Profile
ZS 05
Alternative Names: ZS-05Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Zensun (Shanghai) Sci & Tech
- Class Antibacterials; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Urinary tract infections
- Discontinued Small cell lung cancer
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Urinary-tract-infections in China
- 31 Dec 2018 Discontinued - Preclinical for Small cell lung cancer in China (unspecified route) (Zensun pipeline, December 2018)
- 31 Dec 2018 Preclinical trials in Urinary tract infections in China (unspecified route), before December 2018